n (%) or mean±SD (median) | |
Age, years | 49.5±13.4 (51.6) |
Male | 128 (64%) |
Classified as r-axSpA | 129 (64%) |
Symptom duration, years | 15.2±11.4 (13.0)* |
Diagnostic delay, years | 8.0±7.9 (5.0)* |
HLA-B27 positive | 153 (78%) |
High education level† | 68 (34%) |
Occupational situation | |
Employed | 126 (63%) |
Unemployed | 18 (9%) |
Studying | 5 (3%) |
Retired | 18 (9%) |
Not capable due to axSpA | 32 (16%) |
BMI, kg/m2 | 27.8±5.8 (26.4) |
Current smoker | 51 (26%) |
Current peripheral arthritis‡ | 6 (3%)§ |
History of IBD | 16 (8%) |
History of uveitis | 52 (26%) |
History of psoriasis | 13 (7%) |
BASDAI, 0–10 BASDAI≥4 | 3.9±2.2 (3.6) 93 (47%) |
ASDAS ASDAS≥2.1 | 2.1±0.9 (2.2) 98 (51%) |
CRP, mg/L CRP≥5, mg/L | 4.1±5.9 (2.0) 49 (24%) |
ASQoL, 0–18 | 5.4±4.8 (4.0)* |
BASFI, 0–10 | 3.3±2.4 (2.9)* |
mSQUASH activity total score | 9202±5516 (8960) |
Medication use | |
NSAID use | 117 (59%) |
csDMARD use | 25 (12%) |
bDMARD use | 104 (53%) |
Values are presented in: n (%) or mean±SD (median). All % values exclude missing items for their respective characteristic. All missing values <5% unless otherwise specified.
*10-15% missing
†Defined as International Standard Classification of Education level >5.
‡Defined as a swollen joint count of ≥1.
§5-10% missing.
ASDAS, Axial Spondyloarthritis Disease Activity Score; ASQoL, Ankylosing Spondylitis Quality of Life questionnaire; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; bDMARD, biological disease-modifying antirheumatic drug; BMI, body mass index; CRP, C reactive protein; csDMARD, conventional synthetic DMARD; HLA, human leucocyte antigen; IBD, inflammatory bowel disease; mSQUASH, modified-Short Questionnaire to Assess Health-enhancing physical activity; NSAID, non-steroidal anti-inflammatory drug; r-axSpA, radiographic axial spondyloarthritis.